Insys Therapeutics (INSY) - FREE Research Report

Kapoor John N who is Director at Insys Therapeutics sold 27,428 shares at $47.25 on Dec. 9, 2013. Following this transaction, the Director owned 14.1 million shares meaning that the stake was reduced by 0.19% with the 27,428-share transaction.

The shares most recently traded at $49.44, up $2.19, or 4.44% since the insider transaction. Historical insider transactions for Insys Therapeutics go as follows:

  • 12-Week # shares bought: 1,000
  • 24-Week # shares bought: 6,000

The average volume for Insys Therapeutics has been 261,900 shares per day over the past 30 days. Insys Therapeutics has a market cap of $1.0 billion and is part of the health care sector and drugs industry. Shares are unchanged year-to-date as of the close of trading on Monday.

INSYS Therapeutics, Inc., a development stage company, develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. Currently there are 2 analysts that rate Insys Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on INSY - FREE

TheStreet Quant Ratings rates Insys Therapeutics as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Insys Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

If you liked this article you might like

Market Recon: The Direction of Oil Has Been Somewhat Shocking

Energy Sector Down After the Energy Information Administration reported Oil Inventory Build-up

Diversity Measures on Corporate Boards Have a Breakout Year

Trade-Ideas: Fleetcor Technologies (FLT) Is Today's Post-Market Leader Stock

Analysts' Actions -- Energizer, HollyFrontier, Oracle, Pinnacle Foods and More